Revised forecast
Fiscal year ending August 2026 · Full yearPrevious forecast published 10 April 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Revenue fell below plan due to delays in launching the sales structure for Sovereign GaiXer and in product development, sales and marketing activities, delays in establishing the sales organization and distributor channel for Medical AI Solutions (JV), the loss of some major project-based service contracts, and an increase in cancellations of the cloud version of GaiXer. On the earnings side, the main factors were a decline in gross profit and persistently high fixed costs.
| Item | Details |
|---|---|
| Net Sales | 4,348 million yen → 3,135 million yen（△27.9％） |
| Operating profit | -1,546 million yen → -2,438 million yen（57.7% wider loss） |
| Ordinary income | -1,541 million yen → -2,432 million yen（57.8% wider loss） |
| Profit attributable to owners of the parent | -1,566 million yen → -2,476 million yen（58.1% wider loss） |
| Net income per share | -105.77 yen → -158 yen |
| Fiscal Period Covered | Fiscal year ending August 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 10 April 2026 |
| Previous-period results | Revenue: ¥3,980 million; operating loss: ¥1,729 million; ordinary loss: ¥1,719 million; net loss attributable to owners of the parent: ¥2,117 million; basic loss per share: ¥143.22 (fiscal year ended August 2025) |
| Reason for the revision | Revenue fell below plan due to delays in launching the sales structure for Sovereign GaiXer and in product development, sales and marketing activities, delays in establishing the sales organization and distributor channel for Medical AI Solutions (JV), the loss of some major project-based service contracts, and an increase in cancellations of the cloud version of GaiXer. On the earnings side, the main factors were a decline in gross profit and persistently high fixed costs. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue fell below plan due to delays in establishing the sales structure for Sovereign GaiXer, product development, the sales organization, marketing and preparations for sales promotion, delays in establishing the sales organization and distributor channel for Medical AI Solutions (JV), the loss of major project-based service contracts, and an increase in cancellations of the cloud version of GaiXer. On the earnings side, the main factors were a decline in gross profit and persistently high fixed costs because the Company was unable to sufficiently correct its excessive staffing and organizational structure relative to its revenue level.